Do non-clotting factor therapies work for both Hemophilia A and Hemophilia B?
Non-clotting factor therapies work for both Hemophilia A and Hemophilia B. These treatments help prevent bleeding episodes without replacing the missing clotting factor. Studies show they reduce bleeding rates and improve quality of life for people with either condition.
What the research says
A systematic review found that newer non-clotting factor therapies, such as emicizumab, concizumab, marstacimab, and fitusiran, are being studied for people with congenital Hemophilia A or B 14. These drugs aim to prevent bleeding and reduce complications compared to standard clotting factor treatments 14.
Specific data on concizumab shows it reduced the annualized bleeding rate to a median of 0.8 in patients with inhibitors. This study included patients with both Hemophilia A and Hemophilia B, confirming the drug works for both types 3.
Other non-clotting options like anti-tissue factor pathway inhibitor (TFPI) monoclonal antibodies rebalance coagulation to control bleeding in patients with Hemophilia A 6. Anti-antithrombin therapy is another type of non-clotting factor product developed to help manage bleeding 6.
What to ask your doctor
- Which non-clotting factor therapies are approved for my specific type of hemophilia?
- How do these therapies compare to clotting factor concentrates for my bleeding history?
- What are the side effects of non-clotting factor therapies like emicizumab or concizumab?
- Are there any new non-clotting treatments in clinical trials for my condition?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.